Petros G. Nikolinakos, MD, CPI (Certified Principal Investigator) is University Cancer & Blood Center’s, managing partner. He also serves as the director and principal investigator of UCBC’s clinical research program which conducts numerous trials involving novel targeted therapies, immunotherapies, and breakthrough cancer treatments. Click here for a full list of available clinical trials at UCBC. Dr. Nikolinakos is a clinical Associate Professor at the University of Georgia and Augusta University and is a recipient of the 2013 ASCO Clinical Trials Participation Award.
Dr. Nikolinakos is board-certified in medical oncology, hematology, and internal medicine. He joined UCBC in September 2009 after completing fellowship in Hematology and Oncology at the NCI designated MD Anderson Cancer Center in Houston, Texas where he conducted basic science as well as clinical and translational research. Prior to this, he was a resident and Chief Medical Resident at Chicago’s Cook County Hospital.
An author and cancer researcher, Dr. Nikolinakos has published on a variety of clinical and basic science cancer topics in The New England Journal of Medicine, Journal of Cancer Research, Journal of Clinical Oncology, Oncogene, American Journal of Hematology, Journal of Clinical Investigation, Public Library of Science, and the Journal of Thoracic Oncology. His numerous abstracts have been presented at the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR).
Petros’ passion is driven by the bonds he builds with his patients and their families and the enjoyment he holds in helping others. Dr. Nikolinakos enjoys traveling to Greece to see his family and finds special interest in photography.
A list of current research publications and abstracts are listed below.
David Michael Waterhouse, Leora Horn, Craig H. Reynolds, David R. Spigel, Jason Claud Chandler,Tarek Mekhail, Mohamed K. Mohamed, Ben C. Creelan, Kenneth Bruce Blankstein, Petros Nikolinakos, Michael McCleod, Ang Li, Ian M. Waxman, Nivedita Aanur, Shruti Agrawal. Safety profile of nivolumab administered as 30-minute (min) infusion: Analysis of data from CheckMate 153 (abstr 165497)
Sarina Anne Piha-Paul, James A. Knost, Petros Nikolinakos, Lee Steven Schwartzberg, Denise A. Yardley, Eric Daniel Slosberg, Barinder Kang, Theresa White, Claudia Lebedinsky. Colorectal Cancer (CRC) Cohort Analysis of Patients Treated with Buparlisib in a Disctinctive Tissue-Agnostic Trial Model for Molecularly Pre-Selected Tumors (abstr 140219)
Lindsay Carol Overton, Christopher L. Corless, Manish Agrawal, Vasily J. Assikis, Nancy L. Beegle, Sibel Blau, Marc Chernoff, Stephen G. Divers, David H. Henry, Petros Nikolinakos, Colleen Oliver, Eric Scott Schaefer, Frederick M. Schnell, Dennis Slater, Daniel Lewis Spitz, Vicki Tosher, Robert J. Green; Impact of next-generation sequencing (NGS) on treatment decision in the community oncology setting (abstr 128879)
Owen A. O’Connor, MD, PhD1, Changchun Deng, MD, PhD1, Jennifer E Amengual, MD1, Marshall Schreeder, MD3, Daruka Mahadevan, MD4, Mazen Y. Khalil, MD5, Petros Nikolinakos, MD6, Ahmed Sawas, MD1, Jasmine Zain, MD1, Molly Patterson, MSW1, Sean Clark-Garvey, MPH1, Michelle Mackenzie, RN2, Emily K. Pauli, PharmD3, Kathy Cutter, RN3, Marnie Brotherton, RN4, Amber Moon, RN5, Jamie Hodgson, CRCC6, Christen N. Cooper, RN6, Peter Sportelli7, Hari Miskin7 and Charles M. Farber, MD, PhD2 . Results of a Phase I Dose-Escalation Trial with Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb) for Patients with Rituximab Relapsed/Refractory Lymphoma
Klempner SJ1, Bazhenova LA2, Braiteh FS3, Nikolinakos PG4, Gowen K5, Cervantes CM1, Chmielecki J5, Greenbowe JR5, Ross JS6, Stephens PJ5, Miller VA5, Ali SM5, Ou SH7. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI 2015 Sep;89(3):357-9. doi: 10.1016/j.lungcan.2015.06.021. Epub 2015 Jun 29
Lee S. Schwartzberg, MD; Kurt W. Tauer, MD; Robert C. Hermann, MD; Petros G. Nikolinakos, MD; Arthur C. Houts, PhD. Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive (HER2+) Breast Cancer. J Clin Oncol 31, 2013 (suppl; abstr TPS659)
Lauren Averett Byers, Meera Nanjundan, Luc Girard, Kevin Coombes, Yang Xie, Michael Peyton, Sunny Zachariah, Stephanie Weber, Doris Siwak, Petros Nikolinakos, Gordon Mills, John Minna, and John Heymach. Reverse-phase protein array (RPPA) profiling of response to taxanes and epidermal growth factor receptor (EGFR) inhibitors identifies an inverse correlation between markers of sensitivity to docetaxel and erlotinib in non-small cell lung cancer lines. AACR Meeting Abstracts, Apr 2008; 2008: 3937.
Tina Cascone, Petros Nikolinakos, Li Xu, Matthew Herynk, Monique Nilsson, and John Heymach. Differential regulation hypoxia inducible factor (HIF)-1 and -2 in human NSCLC cell lines bearing wild type and mutated EGFR. AACR Meeting Abstracts, Apr 2008; 2008: 2039.
Petros Nikolinakos, N. Altorki, M. Guarino, H. Tran, D. Rajagopalan, S. Swann, W. Bordogna, L. Ottesen, D. Yankelevitz, J.V. Heymach. Analyses of plasma cytokine/angiogenic factors (C/AFs) profile during preoperative treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 7568) ASCO.
Byers, Lauren Averett, Nanjundan, Meera, Girard, Luc, Coombes, Kevin, Xie, Yang, Peyton, Michael, Ma, Yao, Zachariah, Sunny, Nikolinakos, Petros, Minna, John, Heymach, John. Reverse-phase protein array (RPPA) profile of non-small cell lung cancer lines identifies tumor signatures for sensitivity and resistance to chemotherapy and targeted agents. AACR Meeting Abstracts, 2007: B178e
Richard B. Lanman, Stefanie A. Mortimer, Oliver A. Zill, Dragan Sebisanovic, Rene Lopez, Sibel Blau,Eric A. Collisson, Stephen G. Divers, Dave S. B. Hoon, E. Scott Kopetz, Jeeyun Lee, Petros G. Nikolinakos, Arthur M. Baca, Bahram G. Kermani, Helmy Eltoukhy, AmirAli Talasaz. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell Free Circulating Tumor DNA. PLOS ONE | DOI:10.1371/journal.pone.0140712 October 16, 2015.
Ralph G. Zinner, MD, Coleman K. Obasaju, MD, PhD, David R. Spigel, MD, Robert W. Weaver, MD,
J. Thaddeus Beck, MD, David M. Waterhouse, MD, MPH, Manuel R. Modiano, MD, Borys Hrinczenko, MD, PhD, Petros G. Nikolinakos, MD, Jingyi Liu, PhD, Andrew G. Koustenis, BPharm, Katherine B. Winfree, PhD, Symantha A. Melemed, PhD, Susan C. Guba, MD, Waldo I. Ortuzar, MD, Durisala Desaiah, PhD, Joseph A. Treat, MD, Ramaswamy Govindan, MD, and Helen J. Ross, MD. PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer. J Thorac Oncol. 2015;10: 134-142.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J,Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015; 16: 499-508; 2015 May
Amelia Zelnak, Petros Nikolinakos, Jayanthis Srinivasiah, William Jonas, Andrew Pippas, Yuan Liu, Xiaoxian Li, Mylin Torres, Ruth M. O’Regan. High pathologic complete response in HER2-positive, early-stage breast cancer to a novel non-anthracycline neoadjuvant chemotherapy. Clinical Breast Cancer.
Nikolinakos, PG, Altorki, N, Yankelevitz, D, Tran, H T, Rajagopalan, D, Ottesen, LH, Heymach, JV. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res. 2010 Mar 15;70(6):2171-9.
Xu L, Nilsson MB, Saintignv P, Cascone T, Herynk MH, DU Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV. Epiderman growth factor receptor regulated MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene. 2010 Feb 15.
Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA, Jackson AL, Nikolinakos P, Ospina B, Naumov G, Brandstetter KA, Weigman VJ, Zaghlul S, Hayes DN, Padera RF, Heymach JV, Kung AL, Sharpless NE, Kaelin WG Jr, Wong KK. HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest. 2009 Aug; 119(8):2160-70.
Nikolinakos P, Heymach JV: The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S131-4 Review.
Reilly BM, Clark P, Nikolinakos P: Clinical problem-solving. Easy to see but hard to find. N Engl J Med. 2003 Jan 2; 348(1):59-64.
Koduri PR, Singa P, Nikolinakos P: Autoimmune hemolytic anemia in patients infected with human immunodeficiency virus-1. Am J Hematol. 2002 Jun;70(2):174-6.
Shekarappy RJ, Nikolinakos, P, Bansidhar T, Sistoza E, Smith J. Photo quiz. Back rash. Am Fam Physician. 1999 Sep 1; 60(3):927-8.
Nikolinakos P, Lippman SM. Two Genomic Strategies in Non-Small Cell Lung Cancer Prognosis. Abstracts in Hematology & Oncology. 2007; 10(3):4-7.